$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022004487 Filed on March 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$18.28M	$68.79M	$13.75M
YoY Change	32.92%	50.86%	23.54%
Cost Of Revenue	$9.525M	$32.08M	$4.280M
YoY Change	122.55%	119.84%	20.22%
Gross Profit	$8.751M	$36.71M	$9.470M
YoY Change	-7.59%	18.39%	25.1%
Gross Profit Margin	47.88%	53.36%	68.87%
Selling, General & Admin	$27.70M	$86.84M	$15.81M
YoY Change	75.19%	41.98%	10.33%
% of Gross Profit	316.51%	236.58%	166.95%
Research & Development	$43.05M	$128.9M	$17.96M
YoY Change	139.72%	101.01%	-23.96%
% of Gross Profit	491.99%	351.06%	189.65%
Depreciation & Amortization	$1.251M	$2.600M	$950.0K
YoY Change	31.68%	13.04%	10.47%
% of Gross Profit	14.3%	7.08%	10.03%
Operating Expenses	$70.75M	$215.7M	$33.77M
YoY Change	109.51%	72.19%	-11.01%
Operating Profit	-$62.00M	-$188.5M	-$24.30M
YoY Change	155.15%	100.0%	-20.01%
Interest Expense	-$6.034M	$24.19M	$3.950M
YoY Change	-252.76%	-381.91%	-256.13%
% of Operating Profit
Other Income/Expense, Net		$24.19M
YoY Change		-381.94%
Pretax Income	-$68.04M	-$164.4M	-$20.35M
YoY Change	234.32%	59.8%	-38.26%
Income Tax	$473.0K	$473.0K	$140.0K
% Of Pretax Income
Net Earnings	-$31.57M	-$64.70M	-$5.300M
YoY Change	495.57%	39.07%	-65.78%
Net Earnings / Revenue	-172.71%	-94.06%	-38.55%
Basic Earnings Per Share		-$0.79
Diluted Earnings Per Share	-$377.4K	-$792.0K	-$66.41K
COMMON SHARES
Basic Shares Outstanding		81.70M
Diluted Shares Outstanding		81.70M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$305.7M	$305.7M	$233.4M
YoY Change	31.0%	31.0%	70.49%
Cash & Equivalents	$305.7M	$305.7M	$233.4M
Short-Term Investments
Other Short-Term Assets	$7.066M	$7.066M	$6.700M
YoY Change	5.46%	5.46%	63.41%
Inventory	$9.862M	$9.862M	$1.404M
Prepaid Expenses
Receivables	$23.11M	$23.11M	$23.93M
Other Receivables	$678.0K	$678.0K	$800.0K
Total Short-Term Assets	$346.5M	$346.5M	$266.2M
YoY Change	30.18%	32.44%	70.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.07M	$34.07M	$11.92M
YoY Change	26.36%	5.16%	-4.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$17.60M
YoY Change	-100.0%	-100.0%	58.56%
Other Assets	$1.198M	$3.418M	$1.013M
YoY Change	18.26%	26.59%	-12.52%
Total Long-Term Assets	$50.04M	$50.04M	$67.26M
YoY Change	-25.6%	-25.53%	-4.14%
TOTAL ASSETS
Total Short-Term Assets	$346.5M	$346.5M	$266.2M
Total Long-Term Assets	$50.04M	$50.04M	$67.26M
Total Assets	$396.5M	$396.5M	$333.4M
YoY Change	18.92%	20.59%	47.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$47.43M	$47.43M	$11.41M
YoY Change	315.61%	132.5%	-50.17%
Accrued Expenses	$90.66M	$25.35M	$45.39M
YoY Change	99.74%	14.7%	78.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.510M	$4.510M	$5.300M
YoY Change	-14.91%	-14.91%	-26.39%
Total Short-Term Liabilities	$101.0M	$101.0M	$51.76M
YoY Change	95.21%	110.5%	13.47%
LONG-TERM LIABILITIES
Long-Term Debt	$46.56M	$46.56M	$59.00M
YoY Change	-21.08%	-21.08%	-28.4%
Other Long-Term Liabilities	$2.033M	$23.02M	$1.949M
YoY Change	4.31%	-7.18%	-8.75%
Total Long-Term Liabilities	$2.033M	$69.58M	$1.949M
YoY Change	4.31%	-16.96%	-8.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$101.0M	$101.0M	$51.76M
Total Long-Term Liabilities	$2.033M	$69.58M	$1.949M
Total Liabilities	$170.6M	$287.8M	$136.4M
YoY Change	25.08%	25.96%	-11.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$547.5M		-$482.8M
YoY Change	13.4%		10.67%
Common Stock	$101.0K		$95.00K
YoY Change	6.32%		28.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.7M	$108.7M	$100.3M
YoY Change
Total Liabilities & Shareholders Equity	$396.5M	$396.5M	$333.4M
YoY Change	18.92%	20.59%	47.25%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$31.57M	-$64.70M	-$5.300M
YoY Change	495.57%	39.07%	-65.78%
Depreciation, Depletion And Amortization	$1.251M	$2.600M	$950.0K
YoY Change	31.68%	13.04%	10.47%
Cash From Operating Activities	-$38.70M	-$116.5M	-$20.48M
YoY Change	88.95%	39.27%	-18.24%
INVESTING ACTIVITIES
Capital Expenditures	-$1.957M	$4.566M	-$900.0K
YoY Change	117.44%	137.07%	1.12%
Acquisitions
YoY Change
Other Investing Activities	$55.31M	$45.48M	-$670.0K
YoY Change	-8355.22%	-1225.74%	-155.83%
Cash From Investing Activities	$53.35M	$40.51M	-$1.560M
YoY Change	-3520.06%	-665.52%	-603.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$9.085M
YoY Change		-119.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.94M	149.0M	37.01M
YoY Change	5.22%	-13.58%	36.32%
NET CHANGE
Cash From Operating Activities	-38.70M	-116.5M	-20.48M
Cash From Investing Activities	53.35M	40.51M	-1.560M
Cash From Financing Activities	38.94M	149.0M	37.01M
Net Change In Cash	53.60M	72.97M	14.97M
YoY Change	258.04%	-10.54%	521.16%
FREE CASH FLOW
Cash From Operating Activities	-$38.70M	-$116.5M	-$20.48M
Capital Expenditures	-$1.957M	$4.566M	-$900.0K
Free Cash Flow	-$36.74M	-$121.1M	-$19.58M
YoY Change	87.64%	41.47%	-18.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2028-12-31
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101435505
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94877492
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35366
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5157386
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 301
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Island
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
CY2021	dei	City Area Code CityAreaCode	781
CY2021	dei	Local Phone Number LocalPhoneNumber	652-4500
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	254224038
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Short Hills, NJ
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305744000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	233351000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23112000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23928000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9862000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1404000
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	678000
CY2020Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	744000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7066000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6723000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	346462000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	266150000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15066000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11923000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19005000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20487000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2220000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1645000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	17566000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1198000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1013000
CY2021Q4	us-gaap	Assets Assets	396503000
CY2020Q4	us-gaap	Assets Assets	333413000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	90660000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	45389000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2611000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	345000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2104000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1849000
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	812000
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0
CY2021Q4	fbio	Imputed Interest Related To Partner Company Installment Payments Licenses Current ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent	490000
CY2020Q4	fbio	Imputed Interest Related To Partner Company Installment Payments Licenses Current ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent	778000
CY2021Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	4510000
CY2020Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	4522000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101042000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51760000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	7063000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	8323000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	42937000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	51677000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20987000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22891000
CY2021Q4	fbio	Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent	373000
CY2020Q4	fbio	Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent	863000
CY2021Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	3627000
CY2020Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	8137000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2033000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1949000
CY2021Q4	us-gaap	Liabilities Liabilities	170626000
CY2020Q4	us-gaap	Liabilities Liabilities	136414000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2020Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2021Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2020Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101435505
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94877492
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	101000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	95000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	656033000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	583000000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-547463000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-482760000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	108674000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	100338000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	117203000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	96661000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225877000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196999000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	396503000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	333413000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	63134000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44531000
CY2021	fbio	Collaboration Revenue CollaborationRevenue	5389000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	268000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1068000
CY2021	us-gaap	Revenues Revenues	68791000
CY2020	us-gaap	Revenues Revenues	45599000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32084000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14594000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	113240000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	61275000
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15625000
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2834000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86843000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61166000
CY2021	fbio	Wire Transfer Fraud Loss WireTransferFraudLoss	9540000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	257332000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	139869000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-188541000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-94270000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	649000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1518000
CY2021	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	15308000
CY2020	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	15326000
CY2021	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	39294000
CY2020	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	6418000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	447000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1189000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24188000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8579000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164353000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102849000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100123000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56459000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64703000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-46526000
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.02
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.43
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-1.23
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.78
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81700220
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72005181
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	72532000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	13451000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	253000
CY2020	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	45827000
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6515000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	72000
CY2020	fbio	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	-35543000
CY2020	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	53749000
CY2020	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	70988000
CY2020	fbio	Adjustments To Additional Paid In Capital Preferred Stock Offering Net AdjustmentsToAdditionalPaidInCapitalPreferredStockOfferingNet	7074000
CY2020	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	349000
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	237000
CY2020	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	13000
CY2020	fbio	Partner Companys Exercise Of Options For Cash PartnerCompanysExerciseOfOptionsForCash	13000
CY2020	fbio	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	1216000
CY2020	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	46000
CY2020	fbio	Common Shares Issued For Subordinated Note Financial Interest Expenses CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses	1317000
CY2020	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants In Conjunction With Debt Instrument AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsInConjunctionWithDebtInstrument	4419000
CY2020	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	56459000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-46526000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196999000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	19486000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	278000
CY2021	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	9085000
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	8031000
CY2021	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	-34996000
CY2021	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	-110887000
CY2021	fbio	Partner Companys Exercise Of Options For Cash PartnerCompanysExerciseOfOptionsForCash	7000
CY2021	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	309000
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	749000
CY2021	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	176000
CY2021	fbio	Common Shares Issued For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares	820000
CY2021	fbio	Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Shares AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredShares	21812000
CY2021	fbio	Adjustments To Additional Paid In Capital Conversion Of Derivative Warrant Liabilities AdjustmentsToAdditionalPaidInCapitalConversionOfDerivativeWarrantLiabilities	4628000
CY2021	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	100123000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64703000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225877000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2021	us-gaap	Depreciation Depreciation	2628000
CY2020	us-gaap	Depreciation Depreciation	2280000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	48000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	49000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3914000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5622000
CY2021	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	2845000
CY2020	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	0
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	781000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	697000
CY2021	fbio	Debt Prepayment Penalties DebtPrepaymentPenalties	450000
CY2020	fbio	Debt Prepayment Penalties DebtPrepaymentPenalties	0
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2474000
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	1420000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1689000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1625000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	19486000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13451000
CY2021	fbio	Common Shares Issuable For Service CommonSharesIssuableForService	0
CY2020	fbio	Common Shares Issuable For Service CommonSharesIssuableForService	18000
CY2021	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	176000
CY2020	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	46000
CY2021	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	820000
CY2020	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	0
CY2021	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	0
CY2020	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	1317000
CY2021	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	39294000
CY2020	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	6418000
CY2021	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	447000
CY2020	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	1189000
CY2021	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	15449000
CY2020	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	2788000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-768000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10438000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8458000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	547000
CY2021	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-66000
CY2020	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-121000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	309000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2590000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	185000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-145000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43307000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11101000
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1042000
CY2021	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0
CY2020	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-92000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2611000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	345000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	136000
CY2021	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1856000
CY2020	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1388000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	84000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-187000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116540000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83682000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	11380000
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4038000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4566000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1926000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	400000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1200000
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	56860000
CY2020	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40514000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7164000
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8031000
CY2020	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	6515000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	70000
CY2020	fbio	Payments For Costs Related To Purchase Of Treasury Stock PaymentsForCostsRelatedToPurchaseOfTreasuryStock	2000
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	39075000
CY2020	fbio	Payment Of Costs Related To Issuance Of Series Preferred Stock PaymentOfCostsRelatedToIssuanceOfSeriesPreferredStock	3535000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9085000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	45851000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	278000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	253000
CY2021	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	309000
CY2020	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	349000
CY2021	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	749000
CY2020	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	237000
CY2021	fbio	Proceeds From Partner Companies Sale Of Stock ProceedsFromPartnerCompaniesSaleOfStock	35367000
CY2020	fbio	Proceeds From Partner Companies Sale Of Stock ProceedsFromPartnerCompaniesSaleOfStock	53680000
CY2021	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	110803000
CY2020	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	71072000
CY2020	fbio	Proceeds From Partner Company S Preferred Stock Offering ProceedsFromPartnerCompanySPreferredStockOffering	8000000
CY2021	fbio	Payment Of Costs Related To Partner Company S Preferred Stock Offering PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering	13000
CY2020	fbio	Payment Of Costs Related To Partner Company S Preferred Stock Offering PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering	913000
CY2021	fbio	Proceeds From Exercise Of Equity Grants ProceedsFromExerciseOfEquityGrants	7000
CY2020	fbio	Proceeds From Exercise Of Equity Grants ProceedsFromExerciseOfEquityGrants	26000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5300000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	500000
CY2021	fbio	Proceeds From Partner Company Share Settled Notes ProceedsFromPartnerCompanyShareSettledNotes	16971000
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	7000000
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	6188000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	148994000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	172410000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72968000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81564000
CY2021Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	0
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153432000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6918000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8204000
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	617000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	993000
CY2021	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	3000
CY2020	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	2000
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4419000
CY2020	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	500000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1270000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000
CY2021	fbio	Conversion Of Partner Company Derivative Warrant Liabilities ConversionOfPartnerCompanyDerivativeWarrantLiabilities	21812000
CY2021	fbio	Conversion Of Partner Company Convertible Preferred Shares ConversionOfPartnerCompanyConvertiblePreferredShares	4628000
CY2020	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	7472000
CY2020	fbio	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	1216000
CY2020	fbio	Unpaid Partner Companys At Market Offering Cost UnpaidPartnerCompanysAtMarketOfferingCost	84000
CY2020	fbio	Unpaid Partner Companys Preferred Stock Offering Cost UnpaidPartnerCompanysPreferredStockOfferingCost	13000
CY2021	fbio	Unpaid Partner Companys Debt Offering Cost UnpaidPartnerCompanysDebtOfferingCost	214000
CY2021	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	371000
CY2021	fbio	Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes	362000
CY2020	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	13000
CY2020	fbio	Unpaid At Market Offering Cost UnpaidAtMarketOfferingCost	30000
CY2020	fbio	Retirement Of Preferred Stock RetirementOfPreferredStock	70000
CY2021	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	250000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	207000
CY2021	fbio	Number Of Partner Companies That Are Publicly Traded NumberOfPartnerCompaniesThatArePubliclyTraded	4
CY2021	fbio	Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders	3
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, provisions for product returns, coupons, rebates, chargebacks, discounts, allowances and distribution fees paid by Journey to certain wholesalers, inventory realization, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Certain comparative figures have been reclassified to conform to the current year presentation. The Company reclassified certain return reserves related to sales allowances of $4.6 million from accounts receivable to current liabilities on the consolidated balance sheet at December 31, 2020. This reclassification was deemed to be immaterial.</p>
CY2021Q4	us-gaap	Inventory Net InventoryNet	9862000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1404000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24460000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305744000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	233351000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2220000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1645000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	11394000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3914000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	15308000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	5572000
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	0
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4290000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1404000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18689000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9394000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6766000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15066000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11923000
CY2021	us-gaap	Depreciation Depreciation	2600000
CY2020	us-gaap	Depreciation Depreciation	2300000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	17566000
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15600000
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2800000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9704000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5622000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	15326000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	47429000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	136000
CY2021Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	3240000
CY2020Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	2580000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1489000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1187000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90660000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45389000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11412000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1835000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1236000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8809000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6701000
CY2021Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	7932000
CY2020Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	5007000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19003000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18606000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6451000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3977000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1965000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1964000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1965000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1964000
CY2021Q4	fbio	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	752000
CY2021Q4	fbio	Finite Lived Intangible Assets Net Excluding Assets That Has Not Been Placed In Service FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService	8610000
CY2021Q4	fbio	Intangible Assets Not Yet Placed In Service IntangibleAssetsNotYetPlacedInService	3942000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60450000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60000000
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.1100
CY2021	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	August - 2025
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7063000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8323000
CY2021Q4	fbio	Decrease In Note Payable DecreaseInNotePayable	10450000
CY2020Q4	fbio	Decrease In Note Payable DecreaseInNotePayable	0
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	42937000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	51677000
CY2020Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	518000
CY2021Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	4640000
CY2020Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	461000
CY2021Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	850000
CY2020Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	600000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3833000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2682000
CY2021Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	10603000
CY2020Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	12869000
CY2021Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	217326000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100123000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	117203000
CY2020Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	153120000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56459000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	96661000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21904246
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19216795
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101435505
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94877492
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2741180
CY2019Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.19
CY2019Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	111000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19486000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13451000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1410501
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	684752
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y3M29D
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.18
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	257011
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.57
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1053490
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.02
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	647482
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y7M17D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.33
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1018490
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.04
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	368344
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1018490
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.04
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	368344
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y8M4D
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2019	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P2Y8M23D
CY2020	fbio	Class Of Warrant Or Right Number Of Shares Granted ClassOfWarrantOrRightNumberOfSharesGranted	1849450
CY2020	fbio	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	3.14
CY2020	fbio	Class Of Warrant Or Right Granted Weighted Average Intrinsic Value ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue	101000
CY2020	fbio	Class Of Warrant Or Right Number Of Shares Forfeited ClassOfWarrantOrRightNumberOfSharesForfeited	9
CY2020	fbio	Class Of Warrant Or Right Forfeited Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice	3.00
CY2020	fbio	Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue	2
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4590621
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.17
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	607848
CY2020	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P4Y10M6D
CY2021	fbio	Class Of Warrant Or Right Number Of Shares Expired ClassOfWarrantOrRightNumberOfSharesExpired	60000
CY2021	fbio	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.37
CY2021	fbio	Class Of Warrant Or Right Expired Weighted Average Intrinsic Value ClassOfWarrantOrRightExpiredWeightedAverageIntrinsicValue	0
CY2021	fbio	Class Of Warrant Or Right Number Of Shares Forfeited ClassOfWarrantOrRightNumberOfSharesForfeited	25000
CY2021	fbio	Class Of Warrant Or Right Forfeited Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice	3.00
CY2021	fbio	Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4505621
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.20
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	68800
CY2021	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P3Y11M4D
CY2021	fbio	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	4370621
CY2021	fbio	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	3.23
CY2021	fbio	Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue	8500
CY2021	fbio	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife	P3Y10M9D
CY2014Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P15Y
CY2014Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	2500000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23100000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19000000.0
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3200000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3253000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3246000
CY2021	us-gaap	Sublease Income SubleaseIncome	1835000
CY2020	us-gaap	Sublease Income SubleaseIncome	1873000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	727000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	593000
CY2021	us-gaap	Lease Cost LeaseCost	2145000
CY2020	us-gaap	Lease Cost LeaseCost	1966000
CY2021	fbio	Lessee Lease Portfolio And Other Supplemental Lease Information LesseeLeasePortfolioAndOtherSupplementalLeaseInformation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC Topic 842<i style="font-style:italic;">, Leases</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3366000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2958000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	207000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	634000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3498000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3270000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3206000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3241000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3243000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14014000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30472000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7381000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23091000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000.0
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2021Q4	us-gaap	Dividends Receivable DividendsReceivable	12327000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.01
CY2020Q4	us-gaap	Dividends Receivable DividendsReceivable	13071000
CY2021	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2020	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2021	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4500000
CY2020	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4000000
CY2021	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2020	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	473000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	136000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	251100000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	180994000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	152295000
CY2021Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	31556000
CY2020Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	20628000
CY2021Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	384000
CY2020Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	415000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13560000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	14732000
CY2021Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6965000
CY2020Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7306000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2265000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1570000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	23239000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16326000
CY2021Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	49000
CY2020Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	54000
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	420000
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1075000
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	215000
CY2020Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	41000
CY2021Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	7000
CY2020Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	0
CY2021Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	1883000
CY2020Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	1455000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	261537000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	215897000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	251052000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	203930000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10485000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11967000
CY2021Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5732000
CY2020Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	6050000
CY2021Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	4753000
CY2020Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	1113000
CY2021Q4	fbio	Deferred Tax Liabilities Gain Loss On Deconsolidation Of Caelum DeferredTaxLiabilitiesGainLossOnDeconsolidationOfCaelum	0
CY2020Q4	fbio	Deferred Tax Liabilities Gain Loss On Deconsolidation Of Caelum DeferredTaxLiabilitiesGainLossOnDeconsolidationOfCaelum	4804000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.10
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.11
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.04
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.04
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01
CY2021	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0
CY2020	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2021	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.01
CY2020	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.29
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2021	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	47000000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	us-gaap	Revenues Revenues	68791000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32084000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	128865000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86843000
CY2021	fbio	Wire Transfer Fraud Loss WireTransferFraudLoss	9540000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24188000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2020	us-gaap	Revenues Revenues	45599000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14594000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64109000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61166000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8579000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2021Q4	fbio	Tangible Assets Net TangibleAssetsNet	383951000
CY2021Q4	us-gaap	Assets Assets	396503000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2020Q4	fbio	Tangible Assets Net TangibleAssetsNet	318784000
CY2020Q4	us-gaap	Assets Assets	333413000
CY2021	fbio	Collaboration Revenue CollaborationRevenue	5389000
CY2020	fbio	Collaboration Revenue CollaborationRevenue	0
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	268000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1068000
CY2021	us-gaap	Revenues Revenues	68791000
CY2020	us-gaap	Revenues Revenues	45599000

Files In Submission

Name	View Source	Status
0001558370-22-004487-index-headers.html	Edgar Link	pending
0001558370-22-004487-index.html	Edgar Link	pending
0001558370-22-004487.txt	Edgar Link	pending
0001558370-22-004487-xbrl.zip	Edgar Link	pending
fbio-20211231.xsd	Edgar Link	pending
fbio-20211231x10k.htm	Edgar Link	pending
fbio-20211231x10k002.jpg	Edgar Link	pending
fbio-20211231x10k_htm.xml	Edgar Link	completed
fbio-20211231xex21d1.htm	Edgar Link	pending
fbio-20211231xex23d1.htm	Edgar Link	pending
fbio-20211231xex23d1001.jpg	Edgar Link	pending
fbio-20211231xex23d2.htm	Edgar Link	pending
fbio-20211231xex31d1.htm	Edgar Link	pending
fbio-20211231xex31d2.htm	Edgar Link	pending
fbio-20211231xex32d1.htm	Edgar Link	pending
fbio-20211231xex32d2.htm	Edgar Link	pending
fbio-20211231_cal.xml	Edgar Link	unprocessable
fbio-20211231_def.xml	Edgar Link	unprocessable
fbio-20211231_lab.xml	Edgar Link	unprocessable
fbio-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2021 Q4 Form 10-K Financial Statement

#000155837022004487 Filed on March 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2021 Q4 Form 10-K Financial Statement

#000155837022004487 Filed on March 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio